Vital KSK Holdings Incorporation operates in the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Vital KSK Holdings Incorporation with three other
drug stores in Asia:
Hokuyaku Takeyama Holdings, Inc
sales of 227.79 billion Japanese Yen [US$2.03 billion]
of which 70%
was Pharmaceutical Business),
Hai-O Enterprise Berhad
(461.70 million Malaysian Ringgits [US$111.55 million]
of which 76%
was Multi-Level Marketing), and
Hua Xia Healthcare Holdings Limited
based in Hong Kong
(330.46 million Hong Kong Dollars [US$42.11 million]
Vital KSK Holdings Incorporation reported sales of ¥565.59 billion (US$5.05 billion)
March of 2018.
decrease of 2.7%
versus 2017, when the company's sales were ¥581.08 billion.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Vital KSK Holdings Incorporation had sales
of ¥547.58 billion.
Contributing to the drop in overall sales was the 2.8% decline
in Pharmaceuticals Sales, from ¥552.28 billion to ¥536.84 billion.
There were also decreases in sales in
Other (down 0.2% to ¥28.75 billion)